<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869100</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A00568-35</org_study_id>
    <nct_id>NCT02869100</nct_id>
  </id_info>
  <brief_title>Comparison of Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging of Spine and Sacroiliac Joints for Detection of Inflammatory Lesions in Spondyloarthritis Patients</brief_title>
  <acronym>FNa</acronym>
  <official_title>Comparison of Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging of Spine and Sacroiliac Joints for Detection of Inflammatory Lesions in Patients Affected by Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to compare detection of axial inflammatory lesions in patients affected by&#xD;
      spondyloarthritis (SpA) with sodium fluoride positron emission tomography (PET) and magnetic&#xD;
      resonance imaging (MRI), the reference technique.&#xD;
&#xD;
      It would be interesting to show the superiority of sodium fluoride PET on MRI for diagnosis&#xD;
      of inflammatory lesions. It could be used for diagnostic care but also therapeutic care of&#xD;
      patients with early forms of spondyloarthritis.&#xD;
&#xD;
      Secondary purposes are:&#xD;
&#xD;
        -  To evaluate performances of sodium fluoride PET in detection of SpA peripheral damage&#xD;
           (except spine and sacroiliac joints)&#xD;
&#xD;
        -  To evaluate bone inflammation (axial and peripheral) with sodium fluoride PET and&#xD;
           compare these data to clinic-biologic parameters used in clinical practice (BASDAI,&#xD;
           BASFI, BASMI, sedimentation rate, C-reactive protein (CRP)) and to structural evaluation&#xD;
           (sacroiliac New York, mSASSS and BASRI scoring methods)&#xD;
&#xD;
        -  To study correlation of axial and peripheral bone inflammation (spine and sacroiliac&#xD;
           joints) evaluated with sodium fluoride PET with biologic markers of inflammation and&#xD;
           bone remodeling (MMP-3; DKK-1, IL-6, IL-17, TNF-α).&#xD;
&#xD;
      Known biologic markers of inflammation in SpA are correlated to activity obtained with MRI.&#xD;
      It is interesting to compare to activity obtained with PET. Moreover, it has been recently&#xD;
      showed the disassociation of inflammation and structural progression (anti-TNF treatments do&#xD;
      not prevent structural progression) that is associated to markers of bone remodeling whose&#xD;
      activity is influenced by an activation/inhibition system of biologic markers of&#xD;
      inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance between binary topographic evaluations of bone inflammation in PET data and MRI data</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>presence or absence of inflammatory sites (MRI) or hyperfixation (PET) in 28 sites (24 vertebrae and 4 sacroiliac joints)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concordance between semi-quantitative evaluation of bone inflammation in MRI data and PET data</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>PET: BME score adapted to PET for spine and modified SPARCC score adapted to PET for sacroiliac joints&#xD;
MRI: Berlin score BME for spine and SPARCC score for sacroiliac joints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Structural evaluation with New York score</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural evaluation with mSASSS scores</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural evaluation with BASRI score</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of specific biologic markers of inflammation and bone remodeling in blood</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>MMP-3, DKK-1, IL-6, IL-17, TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard biologic evaluation of sedimentation rate</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard biologic evaluation of C-reactive protein</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of spinal mobility with BASMI index</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of disease activity with BASDAI index</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of functional impact with BASFI index</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Spondyloarthritis Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Spondyloarthritis Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sodium fluoride Positron Emission Tomography</intervention_name>
    <arm_group_label>Spondyloarthritis Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <arm_group_label>Spondyloarthritis Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiography</intervention_name>
    <arm_group_label>Spondyloarthritis Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-50 year-old patients affected by axial or mixed SpA (ASAS criteria) or &gt;18 year-old&#xD;
             patients according to New York criteria&#xD;
&#xD;
          -  Patients with bone marrow edema lesions in sacroiliac joints and/or spine detected&#xD;
             with MRI&#xD;
&#xD;
          -  No therapeutic changes between hospitalization for evaluation of SpA activity and&#xD;
             inclusion visit&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Affiliation to social security plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal or impossibility of signed informed consent&#xD;
&#xD;
          -  Doubt about possible pregnancy in women of childbearing potential&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  History of drug addiction, alcoholism, psychological problems, severe co-morbidities&#xD;
&#xD;
          -  Renal insufficiency (creatinine clearance &lt; 60 ml/min)&#xD;
&#xD;
          -  Juridical protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre OLIVIER, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nancy, Hôpitaux de Brabois, service de Médecine Nucléaire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nancy, Hôpitaux de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>sodium fluoride positron emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Listerine</mesh_term>
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

